United States, China and Japan, had progressed to a birth rate lower than the death rate. Such a shift in the age distribution has had a visible impact on the economy in many regions of the world. In the United States, three workers supported one retiree in 2009, a sharp reduction from a ratio of 16.5: 1 in 1950 (https://www.ssa.gov), a trend that is projected to continue. Given~90% of healthcare costs fall within the last 2 years of life, the implication of population ageing on the global socio-economy cannot be underestimated.
Ageing is associated with a progressive decline in kidney function. Studies have shown that 30% of glomeruli become sclerotic in apparently healthy individuals by age 80. Renal inulin clearance drops by half from 120 mL/min per 1.73 m 2 in ages 20s down to 65 mL/min per 1.73 m 2 in ages >80 years. 3 In the United States, a majority of glomerular diseases in the elderly are secondary to chronic conditions, such as hypertension, diabetes and glomerular ischaemia from diffuse atherosclerotic vascular disease. Primary glomerular diseases have been relatively fewer. However, in patients who undergo kidney biopsy, due to variations in biopsy indication, local biopsy policy and practice style among institutions, the most common glomerular diseases in the elderly, based on the kidney biopsy, have been crescentic glomerulonephritis (GN) associated with ANCA-mediated vasculitis. 4, 5 Similarly, in Europe, the top few kidney diseases from biopsy are crescentic GN, chronic GN, membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS). [6] [7] [8] [9] The kidney disease spectrum in the elderly based on the kidney biopsy varies between Europe/United States and Asia. A recent large single-centre study in China showed that about 3% (n = 851) of all biopsies (n = 29 425) in the years 2003-2012 were from patients ≥65 years of age. 10 The top four most common biopsy diagnoses were membranous nephropathy (28.8%), diabetic nephropathy (9.8%), IgA nephropathy (9.6%) and vasculitis-associated crescentic GN (6.8%). Similar results were shown in other studies in China, Korea and Japan. [11] [12] [13] [14] The difference in the disease spectrum between the Western and Eastern countries could be due to a true difference in disease distribution and/or due to a variation in the indications and local institutional policies for kidney biopsy. Notably, consistent and common findings across geographical and ethnic differences are, as summarized in a recent paper, 15 as follows: (i) MN is the most common biopsy diagnosis if indication for the biopsy is nephrotic syndrome and (ii) crescentic GN associated with ANCA-mediated vasculitis is the most common diagnosis if the indication is acute kidney injury (AKI).
PROS AND CONS OF KIDNEY BIOPSY FOR ELDERLY PATIENTS
Although studies have shown that in the last two decades, there has been a steady increase in the number of kidney biopsies for the elderly, 12, 16 elderly patients remain a small portion of the total biopsies conducted, as illustrated in a recent study, 10 showing that~3% of the total kidney biopsies were on patients aged >65 years. Practice in general has been biased towards limiting biopsy for elderly patients. Fear of more procedure-related complications and leaning towards conservative treatment options for elderly patients could be some of the reasons. Moreover, age-related kidney histological features are thought to be a potential confounding factor. On biopsy, elderly patients may have prominent age-related histological features, such as glomerulosclerosis, tubular atrophy, interstitial fibrosis and arteriolar hyalinosis. It is assumed that it can be difficult to differentiate these background changes from newly developed glomerulotubular pathology. Studies, however, have shown otherwise. Renal biopsies on elderly patients from a single centre in Japan showed no significant increase in kidney biopsyrelated complications for the very elderly (≥80 years) compared with those aged 70-79 and 60-69 years. 17 On the contrary, histological diagnosis in the very elderly had modified treatment for over 78% of the cases, indicating that the biopsy results could potentially alter disease outcomes. Studies in elderly patients in the United States showed similar findings of lacking significant increase in the procedurerelated complication rate, and in two-thirds of patients, treatment strategy was modified based on the biopsy findings. 4 
TREATMENT STRATEGIES FOR ELDERLY PATIENTS WITH KIDNEY DISEASES
Ageing-related pharmacokinetic and pharmacodynamic changes, combined with diminishing functional reserve in multiple organ systems, comorbidity and polypharmacy, render elderly patients at increased risk for drug-related adverse effects and toxicity. In the NEPharm database, 21 the drug clearance and volume parameters in the elderly were significantly different from those in younger adults for 104 drugs, with a generally longer drug half-life (T 1/2 ) in the elderly. For lipophilic drugs, the volume of distribution increases in the elderly as a result of increasing body fat. Consequently, drug dosing should take these features into consideration. 22 Furthermore, volume expansion as a result of overhydration, a relatively common scenario in critically ill elderly patients, must be compensated by raising the loading dose of a number of medications. 23 A general agreement in gerontological pharmacology has been to 'start low and go slow'. 22 For certain anti-infective medications, however, 'hit high, start hard and go fast' could also apply, especially in the setting of acute infection. The treatment goal should be to maximize the therapeutic effects and simultaneously be mindful of ageing-related physiopathological changes to minimize the adverse and toxic effects.
Polypharmacy is common in elderly patients. 24 Drug-drug interaction and prescription of potentially inappropriate medications (PIM, a contradicted medication or greaterthan-maximum recommended dosage based on the kidney function) present a special risk for the elderly. In a 2015 study of elderly dialysis patients in Japan, 25 the elderly frequently take ≥6 medications daily. PIM prescriptions were increased and positively correlated with the number of prescribed medications. Similar results were shown from studies in elderly CKD patients in Europe and the United States. 26, 27 Another aspect of treatment for elderly patients worth emphasizing is that most of the existing treatment guidelines for kidney diseases have been developed based on the study data from younger adults (reviewed in 28 ). Recognition of this limitation and caution using the existing guidelines for elderly patients is of significant importance. similar to the rate in Asia, 14 suggesting an increased occurrence of IgA nephropathy in the very elderly across geographical and ethnic backgrounds. The pathogenesis of primary IgA nephropathy is detailed in recent reviews. 31, 32 There have been limited studies specifically examining the clinicopathological characteristics and outcomes in elderly patients with IgA nephropathy. This is reflected in a 2012 meta-analysis, showing only nine studies in the past three decades containing elderly patients. 33 Only one of the nine studies was designed to evaluate IgA nephropathy in the elderly (aged ≥50 years), and of the 33 patients in that study, only 16 had limited histological information. 34 A total of four publications have since been added to the literature (searchable and in English). They are discussed below and summarized in Table 1 . [35] [36] [37] [38] In a retrospective study of single university centre in Tokyo, Japan, Oshima et al. compared 31 elderly IgA nephropathy patients (≥60 years of age) with middle-aged (40-59 years) and younger-aged (20-39 years) patients. 35 Elderly patients had more comorbidity, lower eGFR and higher degree of proteinuria at the time of kidney biopsy. Histologically, more chronic changes, including glomerulosclerosis and interstitial fibrosis, were found in the elderly. More elderly patients received treatment of renin-angiotensin system (RAS) inhibitors and steroids than patients in the middle-aged and younger-aged groups. In the setting of infection, a unique entity of postinfectious glomerulonephritis (PIGN), IgA-dominant PIGN, should be considered. The entity has been described in detail in several recent papers. [39] [40] [41] It occurs mostly in the elderly with a male-to-female ratio >3 42 and accounted for 17% of total PIGN in elderly patients in one study. 43 IgA-dominant PIGN has a short latent period. The initial recognition of infection often coincides with the onset of glomerulonephritis. The pathogens are often but not always Staphylococcal aureus (both methicillin-sensitive and methicillin-resistant strains). Diabetic and immunocompromised hosts are at increased risk. Histologically, in addition to the classic diffuse proliferative GN on light microscopy, there is dominant IgA deposition in the mesangium and other parts of the glomeruli. About one-third of the cases show cellular or fibrotic crescents and necrosis. Interstitial inflammation and mononuclear leucocytes are often present. Under electron microscopy, characteristics of subepithelial deposits (humps) are present in most cases. PIGN, including IgA-dominant PIGN, in the elderly carries a poor prognosis. With the exception of those with preserved kidney function at the time of kidney biopsy, the majority of patients develop ESRD.
IgA NEPHROPATHY IN ELDERLY PATIENTS
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The mechanisms underlying the IgA-dominant PIGN have been actively investigated. Evidence suggests that the Staphylococcal antigen may act as a super antigen to bind directly to the major histocompatibility complex on antigen-presenting cells. [47] [48] [49] The binding results in a massive T cell activation with subsequent cytokine hyperactivation, leading to polyclonal B cell activation and production of IgA, IgG and IgM. In line with these findings, Sharmin et al. were able to induce IgA-type glomerulonephritis in Balb/c mice by immunizing the rodents with antigens derived from Staphylococcal aureus. In the immunized mice, elevated circulating IgA was demonstrated, and the antigens were detected in the glomeruli. 50 In patients with IgA-dominant PIGN, Staphylococcal antigen (cell envelope antigen: probable adhesin 51 ) was also detected in the affected glomeruli and was colocalized with IgA antibody. 49 Although speculated to involve genetic susceptibility and mucosal and systemic immunogeneses towards certain environmental and microbial pathogens, 52 ,53 the precise mechanisms are yet to be fully elucidated, a knowledge gap calls for continuous investigations. Recently, Okabayashi et al. retrospectively investigated a cohort of 87 elderly (age ≥60 years) and 250 younger adults (18-59 years) with IgA nephropathy in the years 1992-2012 from multiple hospital centres in Tokyo, Japan. 38 At the time of kidney biopsy, elderly patients had a higher number of comorbid conditions, including hypertension, lower eGFR and higher level of proteinuria. Histologically, there were more prominent chronic changes in elderly patients, including glomerulosclerosis, interstitial fibrosis and tubular atrophy.
The authors evaluated the effects of corticosteroids versus RAS inhibitor treatment for the elderly group. 38 The corticosteroid group had a higher degree of proteinuria at the time of kidney biopsy, 2.4 g/24 h versus 1.4 g/24 h in the RAS inhibitor group. One-year follow-up showed a significant reduction in the urine protein excretion in both groups. No significant differences between the effects of steroids and RAS inhibitors were found. At 1 year, 26% of the steroid group and 38% of the RAS inhibitor group had >30% deterioration of eGFR or reached ESRD. The only variable independently predicting kidney disease progression was the level of urine protein excretion at one year after the diagnosis. Predicting outcome for elderly patients with newly diagnosed IgA nephropathy is exceedingly difficult given the coexisting chronic diseases. In 2011, Berthoux et al. published an absolute renal risk (ARR) model to predict ESRD and death for IgA nephropathy patients. 54 The data were derived from a cohort of French patients (mean age 35.9 AE 15.4). ARR score is based on the presence or absence of hypertension, proteinuria >1 g/24 h and severe histopathological lesions. The predictors were verified in a group of patients with Henoch-Schonlein purpura. 55 Recently, Knoop et al. 56 proposed the addition of eGFR and age to the ARR model to improve its prediction performance. The authors first validated ARR in 1134 IgA nephropathy patients (mean age 38 AE 16) from the Norwegian Kidney Biopsy Registry in the years 1988-2012. They then incorporated eGFR and age into the ARR model. A significant increase in the accuracy of risk prediction for ESRD and death was noted. In our Mayo Clinic study of elderly IgA nephropathy patients (mean age 71 AE 5), we were not able to predict a worse outcome using the ARR. 36 One factor that might account for the failure to predict in our cohort is the older age of our study subjects. For the elderly, the incorporation of eGFR and age at the time of biopsy might be useful. In addition to ARR, there have been several ESRD prediction models and scoring systems for IgA nephropathy, generated from younger adults (mean age 30-40). 57-60 They may not be suitable for elderly patients. An age-specific prediction model is needed. Taken together, the existing data suggest that although the occurrence rate in the elderly based on the kidney biopsy differs between Europe/United States and Asia, IgA nephropathy in the elderly has generally similar clinical and histopathological characteristics. Compared with their younger adult counterparts, elderly patients tend to have a higher level of pre-existing comorbidity, higher degree of tubular interstitial fibrosis and vasculopathy on kidney biopsy, faster kidney progression despite treatment and, in two studies, 36, 56 reduced patient survival.
CONCLUSION
Rising life expectancy and declining fertility rates have given rise to population ageing, resulting in a change in healthcare landscape and an ageing-related heath burden. Glomerular diseases in elderly patients are relatively common. The existing literature suggests that timely diagnosis, including kidney biopsy and treatment, can improve outcomes. Kidney biopsy in elderly patients is generally safe and should not be withheld solely because of age. Treatment for the elderly should be individualized, and multiple age-related factors should be taken into the treatment decision-making. Existing guidelines may not always be appropriate for the elderly. IgA nephropathy has been increasingly diagnosed in the elderly. Although the occurrence rate of IgA nephropathy is lower in the Western countries than in Asia, clinical and histopathological characteristics are similar. In patients with intercurrent infection, IgA-dominant postinfectious glomerulonephritis should be suspected and carefully ruled out. IgA nephropathy in the elderly tends to progress faster than in younger adults and is possibly an independent risk factor for mortality.
DISCLOSURE
The authors have no competing conflict of interests.
